# Deletion that include and extend 141-142 appeared de novo in two of three children with impaired humoral immunity 
# and persistent SARS-CoV-2 infection subject to sequencing. In both cases appearing and persisting in some form from day >=120.
# [This is a common site of deletions in VOCs, such as Y144del in B.1.1.7 and overlapping deletions in P.3, AT.1)]
# Truong et al. (2021) https://doi.org/10.1016/j.ebiom.2021.103355 [Journal publication]
L141del;G142del

# Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including
# this combination in Spike.
# Landis et al. (2021) https://doi.org/10.1101/2021.05.08.21256775 [Preprint (MedRxiv); Now published at: https://doi.org/10.1128/mbio.03448-22]
D138H,E554D,D614G

# Dominant (70%) in day 21 of prolonged infection in immunocompromised host on tacrolimus, steroids and convalescent 
# plasma therapy, then nearly disappearing (<5%) by day 27.
# Chen et al. (2021) https://doi.org/10.1101/2021.04.08.21254791 [Preprint (MedRxiv); Now published at: https://doi.org/10.1128/msphere.00480-21]
L243del;A244del;Q493R

# Individual variants appearing at <=30% frequency at day 21 in immunocompromised host on tacrolimus, steroids and convalescent 
# plasma therapy, then appearing all at >95% frequency at day 27.
# Chen et al. (2021) https://doi.org/10.1101/2021.04.08.21254791 [Preprint (MedRxiv); Now published at: https://doi.org/10.1128/msphere.00480-21]
L141del;G142del;V143del;Y144del;E484K

# The so-called "delta F" variant combination previously observed in mink spillover events also emerged in a lymphoma 
# patient (non-Hodgkin diffuse B-cell lymphoma IV stage B) with a long-term COVID-19 infection (4 months) where 18 de novo mutation occureed overall.
# Patient was taking rituximab, the B-cell-depleting agent, and had no detectable neutralizing antibody response.
# Bazykin et al. (2021) https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580 [Preprint (other)]
Y453F;H69del;V70del

# Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised 
# individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71)
# in subsequent sample sequencing.
# Avanzato et al. (2020) https://doi.org/10.1016/j.cell.2020.10.049 [Journal publication]
L141del,G142del,V143del,Y144del

# Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome
# Choi et al. (2020) https://doi.org/10.1056/NEJMc2031364 [Journal publication]
Q183H

# Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome
# Choi et al. (2020) https://doi.org/10.1056/NEJMc2031364 [Journal publication]
N501Y

# Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome
# complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab. 
# Choi et al. (2020) https://doi.org/10.1056/NEJMc2031364 [Journal publication]
T478K,S494P

# Appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome
# Appeared at same time as T478K,S494P but listed separately due to distance and different domains affected in the Spike (i.e. putatively an independent
# mutation from a functional standpoint since the former are from S1, the latter from S2).
# Choi et al. (2020) https://doi.org/10.1056/NEJMc2031364 [Journal publication]
I870V

# Intermittent appearance at Day 128 onward of long infection in patient on escalated immunosupressed starting Day 111
# Choi et al. (2020) https://doi.org/10.1056/NEJMc2031364 [Journal publication]
Q493K

# Based on structural modelling, this change detected on day 128 sequencing in a chronically infected patient 
# would alter an extensive network of polar interactions with antibody residue R94VH, 
# a germline antibody residue that is conserved in all of the potent VH3-53/3-66-derived antibodies isolated from a convalescent donor
# 5 weeks after infection.
# Clark et al. (2021) https://doi.org/10.1016/j.cell.2021.03.027 [Journal publication]
Y489H

# The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7]
# Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.
# Kemp et al. (2020) https://doi.org/10.1101/2020.12.14.422555 [Preprint (BioRxiv); Now published at: https://doi.org/10.1016/j.celrep.2021.109292]
H69del,V70del
